Philipp Suter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philipp Suter has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Brian Lipworth
Scottish Centre for Respiratory Research, University of Dundee
11 shared publications Robert Greig
8 shared publications- Robert Greig
Scottish Centre for Respiratory Research, University of Dundee
8 shared publications Rory Chan
Scottish Centre for Respiratory Research, University of Dundee, Dundee, United Kingdom
7 shared publications- Rory Chan
School of Medicine, University of Dundee, Dundee, United Kingdom
5 shared publications Arlene Shaw
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
Personalized Dupilumab Therapy in Severe Asthma: Real-World Dosing Interval Prolongation Among Early Responders
- 23 October 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
Open AccessPersonalized Dupilumab Therapy in Severe Asthma: Real-World Dosing Interval Prolongation Among Early Responders
- Open Access
- 6 October 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Scottish Airways Research Network (SARN) Delphi Consensus on pre-biologic assessment, clinical remission and post-remission management in severe asthma
- 6 October 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 263
Open AccessScottish Airways Research Network (SARN) Delphi Consensus on pre-biologic assessment, clinical remission and post-remission management in severe asthma
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA2529
Comparing AI and MDT for biologic treatment decisions in severe uncontrolled asthma
Background: Decisions regarding the management of severe asthma are typically made by multidisciplinary team meetings (MDT). Artificial intelligence (AI) may support healthcare professionals across multiple medical specialities. Aim: Our aim was to evaluate the potential role of AI as an adjunct to the severe asthma MDT, with the goal to improve consistency and effectiveness in biologic decision making. Methods: This retrospective cohort study included biologic naïve patients with severe uncontrolled asthma who were referred for consideration of biologic therapy. All cases were discussed at the MDT of NHS Tayside, Scotland, between January 2024 and August 2025. MDT decisions were compared to five AI model recommendations (ChatGPT, Gemini, CoPilot, PerplexityAI, DeepSeek) using Cohen’s kappa, MDT decisions served as a reference. Results: Among the 114 included patients, the mean (SD) age was 54.5 (15.0) years, the ACQ score 2.98 (1.1) and the AER 5.21 (2.1). Agreements between MDT decisions and AI model recommendations were poor (κ=0.143–0.213). Moreover, agreement between AI models ranged from weak to moderate (κ=0.348–0.586). All AI models demonstrated frequent decision errors that were not aligned with current guidelines. Conclusions: Current AI models demonstrate poor concordance with MDT decisions, highlighting their insufficiency as a standalone or adjunctive tools for biologic decision making. MDT decisions therefore remain the gold standard. erj;68/suppl_70/PA2529/F1 F1 F1
- 5 September 2026
- Published by European Respiratory Society (ERS)
- Vol. 68 (suppl 70) , PA2529
Comparing AI and MDT for biologic treatment decisions in severe uncontrolled asthma
Background: Decisions regarding the management of severe asthma are typically made by multidisciplinary team meetings (MDT). Artificial intelligence (AI) may support healthcare professionals across multiple medical specialities. Aim: Our aim was to evaluate the potential role of AI as an adjunct to the severe asthma MDT, with the goal to improve consistency and effectiveness in biologic decision making. Methods: This retrospective cohort study included biologic naïve patients with severe uncontrolled asthma who were referred for consideration of biologic therapy. All cases were discussed at the MDT of NHS Tayside, Scotland, between January 2024 and August 2025. MDT decisions were compared to five AI model recommendations (ChatGPT, Gemini, CoPilot, PerplexityAI, DeepSeek) using Cohen’s kappa, MDT decisions served as a reference. Results: Among the 114 included patients, the mean (SD) age was 54.5 (15.0) years, the ACQ score 2.98 (1.1) and the AER 5.21 (2.1). Agreements between MDT decisions and AI model recommendations were poor (κ=0.143–0.213). Moreover, agreement between AI models ranged from weak to moderate (κ=0.348–0.586). All AI models demonstrated frequent decision errors that were not aligned with current guidelines. Conclusions: Current AI models demonstrate poor concordance with MDT decisions, highlighting their insufficiency as a standalone or adjunctive tools for biologic decision making. MDT decisions therefore remain the gold standard. erj;68/suppl_70/PA2529/F1 F1 F1
- Open Access
- 12 August 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (8)
Improvement of Severe Volume Dependent Airway Closure With Tezepelumab: A Case Report
Severe asthma may be complicated by airway remodeling, manifesting as higher symptom burden, airflow limitation and reduced treatment response. The effect of biologics on lung function changes remains uncertain. We report a 31‐year‐old man with severe uncontrolled asthma and chronic rhinosinusitis with nasal polyposis, characterized by frequent exacerbations, marked type 2 inflammation, and pronounced volume‐dependent airway closure on spirometry with evidence of small airway dysfunction. Despite optimized high‐dose inhaled therapy, disease control remained poor. Treatment with tezepelumab was initiated following multidisciplinary assessment. After 12 months, the patient achieved normalization of symptoms, biomarkers, lung function, and flow–volume loop morphology without any further exacerbations. This case highlights a striking functional recovery associated with thymic stromal lymphopoietin blockade and suggests a potential role for tezepelumab in modifying early airway remodeling beyond symptom control.
- 12 August 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (8)
Open AccessImprovement of Severe Volume Dependent Airway Closure With Tezepelumab: A Case Report
Severe asthma may be complicated by airway remodeling, manifesting as higher symptom burden, airflow limitation and reduced treatment response. The effect of biologics on lung function changes remains uncertain. We report a 31‐year‐old man with severe uncontrolled asthma and chronic rhinosinusitis with nasal polyposis, characterized by frequent exacerbations, marked type 2 inflammation, and pronounced volume‐dependent airway closure on spirometry with evidence of small airway dysfunction. Despite optimized high‐dose inhaled therapy, disease control remained poor. Treatment with tezepelumab was initiated following multidisciplinary assessment. After 12 months, the patient achieved normalization of symptoms, biomarkers, lung function, and flow–volume loop morphology without any further exacerbations. This case highlights a striking functional recovery associated with thymic stromal lymphopoietin blockade and suggests a potential role for tezepelumab in modifying early airway remodeling beyond symptom control.
- Open Access
- 6 July 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (7) , e70188
Relationships Between Bronchodilator Reversibility and Mannitol Airway Hyperresponsiveness in Severe Asthma
- 6 July 2026
- Published by Wiley in Clinical and Translational Allergy
- Vol. 16 (7) , e70188
Open AccessRelationships Between Bronchodilator Reversibility and Mannitol Airway Hyperresponsiveness in Severe Asthma
- Open Access
- 4 June 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004035
BAL lymphocytosis as a predictive marker for drug response and long-term outcome in fibrotic ILD: systematic review
Background: Fibrotic interstitial lung diseases (fILDs) encompass a heterogeneous group of disorders characterised by varying degrees of inflammation and/or fibrosis. The role of bronchoalveolar lavage lymphocytosis (BALL) as a prognostic biomarker and predictor of corticosteroid (CS) response remains uncertain. We investigated whether, in patients with fILD, increased BALL can serve as a marker for CS responsiveness and whether increased BALL may also predict better long-term outcomes following CS therapy compared with patients with lower BALL levels. Methods: A systematic review was conducted. MEDLINE, Embase, Web of Science and Google Scholar were searched up to 4 August 2025. Eligible studies included mainly observational clinical studies evaluating BALL in fILD, with a focus on short-term CS response (6 months) after treatment, including changes in lung function parameters, radiological response and overall and progression-free survival. Study selection, data extraction and quality assessment were performed independently by two reviewers. Disagreements were resolved by consensus. Results: 30 studies involving a total of 3083 patients were included. Increased BALL was associated with better CS response as reflected by improved lung function and increased survival in fILD subtypes, such as hypersensitivity pneumonitis and non-specific interstitial pneumonia. However, BALL thresholds varied, and study heterogeneity precluded meta-analysis. Most studies showed moderate to high risk of bias. Conclusions: Increased BALL may predict CS responsiveness and treatment outcome prediction in fILD; however, clinical implementation remains limited due to insufficient evidence, predominantly observational studies, inconsistent BALL thresholds and heterogeneous results across disease entities. Standardisation and prospective validations are needed to better integrate BALL findings into clinical routine. PROSPERO registration number: CRD420251057631.
- 4 June 2026
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 13 (1) , e004035
Open AccessBAL lymphocytosis as a predictive marker for drug response and long-term outcome in fibrotic ILD: systematic review
Background: Fibrotic interstitial lung diseases (fILDs) encompass a heterogeneous group of disorders characterised by varying degrees of inflammation and/or fibrosis. The role of bronchoalveolar lavage lymphocytosis (BALL) as a prognostic biomarker and predictor of corticosteroid (CS) response remains uncertain. We investigated whether, in patients with fILD, increased BALL can serve as a marker for CS responsiveness and whether increased BALL may also predict better long-term outcomes following CS therapy compared with patients with lower BALL levels. Methods: A systematic review was conducted. MEDLINE, Embase, Web of Science and Google Scholar were searched up to 4 August 2025. Eligible studies included mainly observational clinical studies evaluating BALL in fILD, with a focus on short-term CS response (6 months) after treatment, including changes in lung function parameters, radiological response and overall and progression-free survival. Study selection, data extraction and quality assessment were performed independently by two reviewers. Disagreements were resolved by consensus. Results: 30 studies involving a total of 3083 patients were included. Increased BALL was associated with better CS response as reflected by improved lung function and increased survival in fILD subtypes, such as hypersensitivity pneumonitis and non-specific interstitial pneumonia. However, BALL thresholds varied, and study heterogeneity precluded meta-analysis. Most studies showed moderate to high risk of bias. Conclusions: Increased BALL may predict CS responsiveness and treatment outcome prediction in fILD; however, clinical implementation remains limited due to insufficient evidence, predominantly observational studies, inconsistent BALL thresholds and heterogeneous results across disease entities. Standardisation and prospective validations are needed to better integrate BALL findings into clinical routine. PROSPERO registration number: CRD420251057631.
- Open Access
- 18 May 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (4) , 477-482.e1
Impact of dupilumab on Sino-Nasal Outcome Test–22 (SNOT-22) domains: Focus on the ear
- 18 May 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (4) , 477-482.e1
Open AccessImpact of dupilumab on Sino-Nasal Outcome Test–22 (SNOT-22) domains: Focus on the ear
- Open Access
- 24 March 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 256, 108790
Oscillometry defined small airways dysfunction in patients with severe uncontrolled asthma and preserved spirometry
- 24 March 2026
- Published by Elsevier in Respiratory Medicine
- Vol. 256, 108790
Open AccessOscillometry defined small airways dysfunction in patients with severe uncontrolled asthma and preserved spirometry
- Open Access
- 10 March 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (7) , 791-794
Are Phenotypic Baseline Characteristics Related to Abolition of AHR After Benralizumab and Dupilumab?
Summary: Lower baseline FEV1 and PEF predicted persistence of mannitol airway hyperresponsiveness to biologics. Higher baseline eosinophils predicted abolition of mannitol airway hyperresponsiveness to biologics.
- 10 March 2026
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 56 (7) , 791-794
Open AccessAre Phenotypic Baseline Characteristics Related to Abolition of AHR After Benralizumab and Dupilumab?
Summary: Lower baseline FEV1 and PEF predicted persistence of mannitol airway hyperresponsiveness to biologics. Higher baseline eosinophils predicted abolition of mannitol airway hyperresponsiveness to biologics.